7th Indo Global Diabetes Summit and Medicare Expo
Bangalore Medical College & Research Institute, India
Title: Bromocriptine as an novel antidiabetic drug – Systematic review
Biography: Allen Rodrigues
In May 2009 FDA approved Bromocriptine QR , a central insulin sensitizer, as an antidiabetic drug either as monotherapy or as an add on therapy for type 2 diabetes. This systematic review is undertaken to assess the efficacy and safety of bromocriptine-QR in adults with type 2 diabetes mellitus based on randomized controlled trials published in peer-reviewed journals. We performed a comprehensive literature search of Google, Pubmed/Medline, Embase, Scopus and the Cochrane Library up to September 2015. Randomized controlled trials of bromocriptine-QR therapy in type 2 diabetes mellitus were eligible. Information was collected concerning basic study data, patient characteristics, methodological quality, efficacy and safety outcomes. There were seven randomized controlled trials on bromocriptine QR as add on therapy. All seven trials revealed a statistically significant (P < 0.05) reduction in glycemic markers in bromocriptine group. Compared to placebo group Bromocriptine-QR as add-on therapy lowered hemoglobin A1c with weighted mean difference − 0.67 , 95% CI − 0.76 to − 0.45. Similarly FBS was reduced with weighted mean difference 18mg/dl, 95% CI 14mg/dl to 23mg/dl and PPBS was reduced with weighted mean difference 28mg/dl, 95% CI 24mg/dl to 33mg/dl. Safety data show that nausea, headache, vomiting, somnolence, and hypoesthesia commonly reported (7-11%) . But they are mild and transient. Moreover Bromocriptine-QR group had no increased risk of hypoglycaemia, hypotension and positive cardiovascular effects. In conclusion bromocriptine-QR therapy offers an attractive alternative option to currently available oral anti diabetic agents for type 2 diabetes mellitus because of novel mechanism of action, good side effect profile and its effects to reduce cardiovascular event rates.